Pharsight

Actoplus Met Xr is owned by Takeda Pharms Usa.

Actoplus Met Xr contains Metformin Hydrochloride; Pioglitazone Hydrochloride.

Actoplus Met Xr has a total of 5 drug patents out of which 0 drug patents have expired.

Actoplus Met Xr was authorised for market use on 12 May, 2009.

Actoplus Met Xr is available in tablet, extended release;oral dosage forms.

The generics of Actoplus Met Xr are possible to be released after 31 July, 2026.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8668931	TAKEDA PHARMS USA	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative	Sep, 2023 (3 months from now)
US8470368	TAKEDA PHARMS USA	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative	Sep, 2023 (3 months from now)
US9060941	TAKEDA PHARMS USA	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative	Sep, 2023 (3 months from now)
US7785627	TAKEDA PHARMS USA	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative	Jul, 2026 (3 years from now)
US7959946	TAKEDA PHARMS USA	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative	Jul, 2026 (3 years from now)